Press release
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven
About this update from Jyong Biotech Ltd.
[{"type":"text","content":"New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the “MOU”) with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market. Under the terms of the MOU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution. There can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated. Fu Feng Kuo, CEO and Chairwoman of Jyong Biotech, commented, “This MOU represents an important step in our Asia‑focused strategy to bring plant‑derived MCS therapies to new markets. Vietnam presents meaningful opportunities for patient access and local partnership, and we are committed to working closely with our prospective partner to evaluate viable regulatory and commercial pathways while safeguarding the scientific and clinical integrity of MCS‑2.” The MOU follows Jyong Biotech’s previously announced non‑binding Letter of Intent with a South Korean pharmaceutical company to evaluate in‑licensing and development opportunities for plant‑derived MCS products, announced on November 24, 2025. As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urina...